Evaluate EGFR Mutation Status and Impact Factors in North China
NCT02620657 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2809
Last updated 2019-08-02
Summary
Approximately 3000 advanced NSCLC patients, who fulfil the inclusion/exclusion criteria, will be recruited by 30 sites in North China.
Conditions
Interventions
- OTHER
-
Non interventional study
Non interventional study
Sponsors & Collaborators
-
ying cheng
lead OTHER
Principal Investigators
-
CHENG NA Ying, Dr. · Jilin Provincial Tumor Hospital
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-12-31
- Primary Completion
- 2017-11-08
- Completion
- 2017-11-08
More Related Trials
-
A Retrospective Study About Treatment Strategy After First/Second Line EGFR-TKI Failure
NCT02618590 ·Status: UNKNOWN
-
Study of EGFR-TKI to Asymptomatic Brain Metastases of NSCLC
NCT02250846 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Predict Gefitinib' s Efficacy for Lung Cancer by Plasma Free Nucleic Acids EGFR Gene Mutation Test
NCT02738684 ·Status: UNKNOWN
-
High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC
NCT02960607 ·Status: UNKNOWN ·Phase: PHASE2
-
Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation
NCT02961270 ·Status: UNKNOWN ·Phase: PHASE2
-
Study on Potential Biomarkers Associated With Clinical Phenotype of EGFR-TKIs in No-small Cell Lung Cancer in China
NCT02381808 ·Status: UNKNOWN
-
A Prospective Observational Study Evaluating c-MET Expression and EGFR Gene Mutation Correlation With Erlotinib Response
NCT01523340 ·Status: COMPLETED
-
EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC
NCT02988141 ·Status: UNKNOWN
-
A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer
NCT05991193 ·Status: RECRUITING
-
Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC
NCT04304638 ·Status: UNKNOWN
-
A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment
NCT01994057 ·Status: RECRUITING
-
Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC
NCT05536505 ·Status: RECRUITING ·Phase: PHASE2
-
A Prospective, Multicenter, Non-interventional, Real-world Study to Characterize Changes in Molecular Markers After Three Weeks of Targeted Therapy With Oxitinib in EGFRm NSCLC
NCT06422546 ·Status: RECRUITING
-
Icotinib for Completed Resected IB NSCLC With EGFR Mutation
NCT02264210 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Learn About the Tests Looking for a Gene Mutation in Adults With Lung Cancer in China (ELEGANT)
NCT05737849 ·Status: WITHDRAWN
-
Immunotherapy in Uncommon and 20ins EGFR-mut Lung Cancers
NCT06164574 ·Status: COMPLETED
-
Study of Chemotherapy Plus Icotinib to Treat EGFR Mutation-positive Non-small-cell Lung Cancer
NCT02272127 ·Status: UNKNOWN ·Phase: PHASE2
-
High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases
NCT02726568 ·Status: UNKNOWN ·Phase: PHASE2
-
Detection of EGFR Mutations in the Blood of Patients With Non-small Cell Lung Cancer: a Feasibility Study
NCT00717002 ·Status: COMPLETED
-
Acquired Resistant Mechanism of the First-generation EGFR TKIs
NCT02804217 ·Status: UNKNOWN
-
Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy
NCT04207775 ·Status: COMPLETED
-
Comprehensive Analysis of Gene Mutation Profile in Chinese NSCLC Patients by Next-generation Sequencing
NCT03609918 ·Status: COMPLETED
-
Study to Evaluate Concordance of Detecting EGFR (Epidermal Growth Factor Receptor) Mutation by Circulating Tumour Free DNA Versus Tissues Biopsy in NSCLC (Non-small Cell Lung Cancer).
NCT03562819 ·Status: COMPLETED
-
NGS Combined With RNAseq on Tumor Immune Escape in NSCLC
NCT03764917 ·Status: UNKNOWN
-
A Multicenter Prospective Study to Assess the Effects of Adjuvant Icotinib in EGFRm Stage I NSCLC With High-risk of Disease Recurrence After Complete Resection
NCT05514314 ·Status: UNKNOWN ·Phase: PHASE2